코로나19로 각성한 전세계 생명과학계...모든 바이러스 치료제 개발 나선다 donga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from donga.com Daily Mail and Mail on Sunday newspapers.
"제2의 코로나 위기는 없다"… 과학자들 힘 합쳐 '神의 치료제' 개발 추진 donga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from donga.com Daily Mail and Mail on Sunday newspapers.
Share this article Share this article SAN FRANCISCO, March 12, 2021 /PRNewswire/ Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, announced that apremilast (Otezla), made by Amgen, has been dropped for futility. Apremilast was chosen for testing in the I-SPY COVID Trial because it is a phosphodiesterase-4 (PDE4) inhibitor hypothesized to blunt the cytokine storm that accompanies critical illness associated with COVID-19. The I-SPY COVID Trial is a phase II, open label, adaptive platform trial being conducted in critically ill COVID-19 patients who are receiving high flow oxygen or mechanical ventilation. The trial was designed to rapidly screen agents to find those with the best chance of reducing time to recovery (defined as reduction in oxygen demand) by approximately 50% and reducing risk of death. The I-SPY COVID Trial identified the initial agents for the study through a unique partnership with the COVID R&D Alliance, and apremilast was the first agent identified and approved to go forward through this mechanism.